OCCIDENT
VC Fund
Zug, Switzerland
Occident is an international, privately held investment company based in Zug and Munich. Our goal is to manage our own wealth in a sustainable, meaningful manner seeking to make a positive contribution to society through our investments. Venture Capital is the focus of our investment activities. We see ourselves as a long-term oriented enabler forinnovative start-ups and visionary founders. As a complementary team of experts, we are fascinated by technologically sound topics (deep tech) from the life sciences, digital and high-tech sectors with the potential to decisively improve people's lives.
- Total investments:
- 39
- Last investment:
- Lead investor:
- 33%
Last updated:
For AI agents: llms.txt
Industries OCCIDENT invests in
Stages OCCIDENT invests in
Countries OCCIDENT invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $758k–$4.6M
- Series A
- $2.2M–$12M
- Series B
- $5.5M–$139M
Investment Focus
Industry
- Health Care 13 (33%)
- Biotechnology 10 (26%)
- Medical Device 7 (18%)
- Medical 5 (13%)
- Therapeutics 4 (10%)
Stage
- Series A 10 (26%)
- Seed 6 (15%)
- Series B 5 (13%)
- Series C 5 (13%)
- Series D 3 (8%)
Country
- Switzerland 12 (31%)
- Germany 10 (26%)
- Finland 1 (3%)
- Slovenia 1 (3%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Cédric Barra
Senior Investment Manager (Life Sciences)
|
Senior Investment Manager (Life Sciences) | Total investments: 10 | Find email | |
Mirco Müller
Junior Investment Manager (Life Sciences)
|
Junior Investment Manager (Life Sciences) | Total investments: 1 | Find email | |
Paul Sunzenauer
Junior Investment Manager (Life Sciences)
|
Junior Investment Manager (Life Sciences) | Total investments: 1 | Find email | |
Simon Schild von Spannenberg
Investment Manager (Industrial Tech)
|
Investment Manager (Industrial Tech) | Total investments: 3 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Immitra Bio
|
At Immitra Bio, we are developing a unique genetic medicine platform that combines two of the most powerful biomedical technologies: hematopoietic stem cells (HSCs) and CRISPR-Cas9 gene editing. Our novel technique allows for precise and long-lasting gene alterations within blood stem cells, resulting in transformational treatments for uncommondiseases with significant unmet medical needs. | $2.8M / Pre-Seed / Jul 21, 2026 | |
Tubulis
|
Tubulis is a biotechnology company that develops antibody-drug conjugates (ADCs) for targeted cancer therapy. The company combines proprietary technologies with disease-specific biological insights to create highly stable and effective protein-drug conjugates. Its platform enables the design of ADCs with improved delivery, reduced toxicity, andenhanced therapeutic potential across various cancer types, including solid and hematologic tumors. Tubulis is advancing a pipeline of experimental drug candidates, such as TUB-040 and TUB-030, which are currently being evaluated in clinical settings for cancers like ovarian and lung cancer. The company also collaborates with industry partners and leverages its proprietary conjugation technologies to expand the scope and effectiveness of targeted oncology treatments. | $400.6M / Series C / Oct 15, 2025 | |
Lymphatica Medtech
|
Lymphatica Medtech is a medical device development company developing a minimally invasive solution for chronic lymphedema.Lymphedema is the chronic swelling that generally occurs in the arms or the legs.Lymphedema is most commonly caused by the removal of or the damage to the lymph nodes as a part of cancer treatment. It results from ablockage in the lymphatic system, which is part of the immune system. The blockage prevents the lymphatic system from draining excess fluids, and the fluid buildup leads to swelling, infections, and pain.Unfortunately, there is no cure for lymphedema. It can be managed with early diagnosis and diligent care of the affected limb, through daily compression, bandages, and manual drainage sessions. From the moment of the diagnosis, the life of lymphedema patients changes forever.Cancer and cancer-related interventions (i.e. surgery, radiotherapy) are frequent causes of lymphedema occurring both in the upper and lower limbs. Breast cancer survivors are at high risk for developing lymphedema, as well as patients treated for melanoma, pelvic and head and neck cancer or other cancer treatments that require lymph node dissection. Physical trauma can also result in lymphedema, a major cause of lymphatic disease among wounded veterans.Lymphedema is associated with significantly impaired quality of life, skin changes, increased risk of infection and in rare cases lymphedema itself may undergo malignant transformation.Lymphatica offers a permanent solution that will allow patients to regain their normal lifestyle. | $19.6M / Series B / Oct 08, 2024 | |
Hemotune
|
Hemotune is a medical device company that develops a therapeutic blood purification platform for treatment of health ailments. | $15.6M / Series B / Mar 25, 2024 | |
|
Tubulis
|
Tubulis is a biotechnology company that develops antibody-drug conjugates (ADCs) for targeted cancer therapy. The company combines proprietary technologies with disease-specific biological insights to create highly stable and effective protein-drug conjugates. Its platform enables the design of ADCs with improved delivery, reduced toxicity, andenhanced therapeutic potential across various cancer types, including solid and hematologic tumors. Tubulis is advancing a pipeline of experimental drug candidates, such as TUB-040 and TUB-030, which are currently being evaluated in clinical settings for cancers like ovarian and lung cancer. The company also collaborates with industry partners and leverages its proprietary conjugation technologies to expand the scope and effectiveness of targeted oncology treatments. | $139.3M / Series B / Mar 14, 2024 | |
Altavo
|
Altavo operates as a medical device startup. Altavo harness the power of machine learning and state-of-the-art sensor technology to improve the lives of people who have lost their voice. | $5.4M / Series A / Feb 20, 2024 | |
Chipmetrics
|
Test chip, test elements and test wafer business concept builder for advanced materials and microelectronics manufacturing. Expert in thin film conformality characterization. Mission is to accelerate applications of conformal 3D thin films. Main product line: PillarHall test chips. | $2.6M / Seed / Jan 24, 2024 | |
ReCatalyst
|
ReCatalyst develops next-generation PEM fuel cell catalysts. | $1.9M / Seed / Jul 12, 2023 | |
EBAMed
|
EBAMed SA is a Swiss startup based in Geneva whose mission is to enable safe and effective non-invasive treatments of heart arrhythmias with protontherapy. The company is currently developing a medical device to enable non-invasive heart motion imaging and real-time synchronization of the therapeutic beam. This device consists in both hardware andsoftware components and expands treatment possibilities for existing protontherapy centres, enabling them for the first time to treat heart patients. | $15.7M / Series A / Jun 27, 2023 | |
Lunaphore
|
Lunaphore Technologies S.A. is a Swiss company born with the vision of accelerating cancer research by bringing the field of spatial biology into mainstream laboratories. Lunaphore has developed its innovative spatial biology solutions based on an award-winning technology called FFeX (Fast Fluidic Exchange). Lunaphore has been recognized as one ofthe most innovative companies internationally. | $32.7M / Series D / Mar 23, 2023 | |
| See all 39 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does OCCIDENT invest in?
OCCIDENT invests primarily in Health Care, Biotechnology and Medical Device startups, most often at Series A and Seed stage. Most of the 39 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is OCCIDENT's check size?
OCCIDENT typically joins rounds of $758k–$4.6M at Seed, $2.2M–$12M at Series A and $5.5M–$139M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds OCCIDENT participates in.
How do I contact OCCIDENT?
Public channels for OCCIDENT include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at OCCIDENT?
The team at OCCIDENT includes Cédric Barra (Senior Investment Manager (Life Sciences)), Mirco Müller (Junior Investment Manager (Life Sciences)) and Paul Sunzenauer (Junior Investment Manager (Life Sciences)). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
